# Advances in Bioprinting to Model Immune‐Mediated Skin Diseases

## TL;DR

This paper reviews how bioprinting is being used to create better skin disease models for medical research and product testing.

## Contribution

The paper provides a focused review on bioprinting advancements for modeling immune-mediated skin diseases.

## Key findings

- Bioprinting improves the reproducibility and scalability of in vitro skin models.
- 3D bioprinting supports the development of models that mimic immune-mediated skin diseases.
- The technology aligns with reducing animal testing through more accurate human-like models.

## Abstract

Chronic, non‐communicable inflammatory skin diseases, are a group of inflammatory conditions with high prevalence across the world and represent a significant challenge in medicine, due to the high number of patients arriving for medical consultations. The development of engineered skin tissue models aims to create advanced in vitro models that accurately recapitulate various skin disorders. Furthermore, the introduction of the 3Rs framework to reduce animal testing, alongside specific legislation intended to minimize such testing, has driven research toward developing in vitro models that closely imitate human conditions and skin pathologies, while also being suitable for testing new therapeutic and cosmetic products. In this context, advancements in bioprinting technologies, which promise to ensure consistent quality, reduce technical variances, and enable upscaling, can improve the reproducibility and performance of such models. This work discusses current advancements in the field of bioprinting of in vitro skin models with a particular focus on their application in the research of immune‐mediated diseases.

This review explores how 3D bioprinting drives innovation in developing in vitro skin models that mimic immune‐mediated diseases. It highlights current technologies, key applications in studying skin pathologies, and emerging challenges. The review points toward future opportunities for improving disease modeling and advancing therapeutic and cosmetic testing.